[The combination on conjugated estrogens and medroxyprogesterone in the post-menopause patient and risk of breast cancer: analysis of an uncertain statistic].
Palma-Aguirre
José Antonio
JA
Unidad de Investigación Médica en Farmacología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Av. Cuauhtémoc 330, Col. Doctores, 06720 México, D.F.
del-Razo
Oscar E
OE
D001943:Breast Neoplasms / Q000453:epidemiology*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000494:pharmacology; D017698:Postmenopause; D045167:Progesterone Congeners / Q000494:pharmacology; D012306:Risk
D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D008525:Medroxyprogesterone